The modern treatment of heart failure is characterized by early intervention, multidimensional care and extended therapy options. Around half of all heart failure patients have a reduced left ventricular ejection fraction. With regard to drug therapy, according to ESC guidelines, there are four standard recommended drug classes that should be used early in HFrEF, as they are particularly important for reducing morbidity and mortality. SGLT-2 inhibitors are now recommended for HFrEF, HFmrEF and HFpEF.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Autoimmune Liver Diseases
Innovative Treatment Approaches for PBC, PSC, and AIH: What’s New?
- Myelofibrosis
Mutations and Molecular Diagnostics in Treatment Decisions
- Psoriasis in the Age of Precision Medicine
Systemic Therapy for Patients with Comorbidities: What Is the Best Choice?
- The AMALFI study and the limits of digital screening for atrial fibrillation
Remote monitoring for atrial fibrillation: lots of detection, little stroke prevention?
- MASH
Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges?
- Obesity Treatment
Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward
- Older patients with atopic dermatitis
Why the Use of Biologics Is Recommended
- Disorders of the Gut-Brain Interaction